# Harmony Biosciences (HRMY) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/HRMY
## Company Profile
- Ticker: HRMY
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CNS
## Stock Data
- Close: 39.77 USD
- Market cap: 1789462615.16 USD
- Last updated: 2026-08-12
## Business Overview
### Sleep and Neurologic Disorders
Harmony Biosciences develops and commercializes medicines for rare neurologic diseases. Its business is anchored by therapies that regulate wakefulness and sleep-wake signaling.
### WAKIX Franchise
WAKIX, or pitolisant, is a histamine H3 receptor antagonist/inverse agonist used in narcolepsy and is the company's principal commercial product.
### Pitolisant Lifecycle Programs
Harmony is extending pitolisant through a gastro-resistant formulation, a higher-dose program and a newly acquired amorphous form intended to support additional central-nervous-system indications.
### Orexin-2 Program
BP-205 is an orexin-2 receptor agonist in Phase 1 development and is intended to complement Harmony's existing wake-promoting franchise with a distinct mechanism.
## Why The Stock Is Moving

As of Aug 12, 2026, HRMY closed up 0.63% at $39.77. No new same-company headline was identified in the current news window.

## Future Catalysts

- NDA submission for a gastro-resistant formulation of pitolisant in the second quarter of 2026.
- Phase 1 pharmacokinetic data for BP-205 around mid-2026.
- Phase 3 data for high-dose pitolisant in 2027.

## Recent News
- 2026-08-06 12:05 EST — [Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium](https://biopharmsignal.com/news/HRMY/harmony-biosciences-to-participate-in-piper-sandler-virtual-cns-symposium-cef5c361) — Source: Harmony Biosciences
- 2026-08-04 11:30 EST — [Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile](https://biopharmsignal.com/news/HRMY/harmony-biosciences-announces-record-q2-2026-revenue-and-shares-initial-clinical-92065642) — Source: Harmony Biosciences
- 2026-07-21 12:05 EST — [Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026](https://biopharmsignal.com/news/HRMY/harmony-biosciences-to-report-second-quarter-2026-financial-results-on-august-4--140a8f01) — Source: Harmony Biosciences
- 2026-07-16 12:30 EST — [Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition](https://biopharmsignal.com/news/HRMY/harmony-biosciences-preannounces-record-quarterly-revenue-for-q2-2026-reaffirms--db1c81b5) — Source: Harmony Biosciences
- 2026-06-11 12:05 EST — [Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting](https://biopharmsignal.com/news/HRMY/harmony-biosciences-announces-poster-presentations-at-2026-sleep-annual-meeting-fe33047a) — Source: Harmony Biosciences